Skip to main content

STK-03: Anticoagulation Therapy for Atrial Fibrillation/Flutter

CBE ID
0436
Endorsement Status
Endorsed with Reserve Status
1.1 New or Maintenance
Maintenance
Previous Endorsement Cycle
Full Year 2015
Is Under Review
No
1.3 Measure Description

This measure captures the proportion of ischemic stroke patients with atrial fibrillation/flutter who are prescribed anticoagulation therapy at hospital discharge.

This measure is a part of a set of eight nationally implemented measures that address stroke care (STK-1: Venous Thromboembolism (VTE) Prophylaxis, STK-2: Discharged on Antithrombotic Therapy, STK-4: Thrombolytic Therapy, STK-5: Antithrombotic Therapy By End of Hospital Day 2, STK-6 Discharged on Statin Medication, STK-8: Stroke Education, and STK-10: Assessed for Rehabilitation) that are used in The Joint Commission’s hospital accreditation and Disease-Specific Care certification programs.

    • 1.14 Numerator

      Ischemic stroke patients prescribed anticoagulation therapy at hospital discharge

    • 1.15 Denominator

      Ischemic stroke patients with documented atrial fibrillation/flutter.

    • Exclusions

      • Less than 18 years of age
      • Length of Stay > 120 days
      • Comfort measures only documented
      • Enrolled in clinical trials related to stroke
      • Admitted for elective carotid intervention
      • Discharged to another hospital
      • Left against medical advice
      • Expired
      • Discharged to home for hospice care
      • Discharged to a health care facility for hospice care
      • Documented reason for not prescribing anticoagulation therapy at discharge

    • 1.13a Data dictionary not attached
      No
    • Most Recent Endorsement Activity
      Endorsed with Reserve Status Neurology Project 2015-2016
      Initial Endorsement
      Last Updated
    • Steward
      The Joint Commission
      Steward Organization POC Email
      [email protected]
      Steward Organization Copyright

      No royalty or use fee is required for copying or reprinting this manual, but the following are required as a condition of usage: 1) disclosure that the Specifications Manual is periodically updated, and that the version being copied or reprinted may not be up-to-date when used unless the copier or printer has verified the version to be up-to-date and affirms that, and 2) users participating in Joint Commission accreditation, including ORYX® vendors, are required to update their software and associated documentation based on the published manual production timelines.

    • Risk Adjustment
      No risk adjustment or risk stratification
      Risk adjustment approach
      Off
      Risk adjustment approach
      Off
      Conceptual model for risk adjustment
      Off
      Conceptual model for risk adjustment
      Off